Evidence map›Paper›PMID 38035132›Full record

ArticlePathogens & immunity2023

Dynamics of T-cell Responses Following COVID-19 mRNA Vaccination and Breakthrough Infection in Older Adults.

Sneha Datwani, Rebecca Kalikawe, Francis Mwimanzi, Sarah Speckmaier, Richard Liang, Yurou Sang, Rachel Waterworth, Fatima Yaseen, Hope R Lapointe, Evan Barad and 7 more

Open access · diamondAbstract read
In one paragraph

Article in Pathogens & immunity, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Sneha DatwaniFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
Rebecca KalikaweFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
Francis MwimanziFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
Sarah SpeckmaierBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
Richard LiangBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
Yurou SangFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
Rachel WaterworthFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
Fatima YaseenDepartment of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, Canada.
Hope R LapointeBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
Evan BaradFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
Mari L DeMarcoDivision of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, Canada.
Daniel T HolmesDivision of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, Canada.
Janet SimonsDivision of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, Canada.
Julio S G MontanerDepartment of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, Canada.
Marc G RomneyDivision of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, Canada.
Zabrina L BrummeFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
Mark A BrockmanFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
Simon Fraser University · CAAIDS Vancouver · CAUniversity of British Columbia · CASt. Paul's Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: While older adults generally mount weaker antibody responses to a primary COVID-19 vaccine series, T-cell responses remain less well characterized in this population. We compared SARS-CoV-2 spike-specific T-cell responses after 2- and 3-dose COVID-19 mRNA vaccination and subsequent breakthrough infection in older and younger adults. Methods: We quantified CD4+ and CD8+ T-cells reactive to overlapping peptides spanning the ancestral SARS-CoV-2 spike protein in 40 older adults (median age 79) and 50 younger health care workers (median age 39), all COVID-19 naive, using an activation-induced marker assay. T-cell responses were further assessed in 24 participants, including 8 older adults, who subsequently experienced their first SARS-CoV-2 breakthrough infection. Results: A third COVID-19 mRNA vaccine dose significantly boosted spike-specific CD4+ and CD8+ T-cell frequencies to above 2-dose levels in older and younger adults. T-cell frequencies did not significantly differ between older and younger adults after either dose. Multivariable analyses adjusting for sociodemographic, health, and vaccine-related variables confirmed that older age was not associated with impaired cellular responses. Instead, the strongest predictors of CD4+ and CD8+ T-cell frequencies post-third-dose were their corresponding post-second-dose frequencies. Breakthrough infection significantly increased both CD4+ and CD8+ T-cell frequencies, to comparable levels in older and younger adults. Exploratory analyses revealed an association between HLA-A*02:03 and higher post-vaccination CD8+ T-cell frequencies, which may be attributable to numerous strong-binding HLA-A*02:03-specific CD8+ T-cell epitopes in the spike protein. Conclusion: Older adults mount robust T-cell responses to 2- and 3-dose COVID-19 mRNA vaccination, which are further boosted following breakthrough infection.

Indexed as

activation-induced marker assaycellular immune responseCOVID-19mRNA vaccinesolder adults

Identifiers

PMID38035132
PMCPMC10686373
OpenAlexW4388795885

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.